AstraZeneca has entered into an agreement to acquire CinCor Pharma, a clinical-stage biopharmaceutical company, focused on developing treatments for resistant and uncontrolled hypertension as well as chronic kidney disease.
As part of the deal, the company will acquire CinCor’s candidate drug, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood pressure lowering in treatment-resistant hypertension.
Baxdrostat represents a potentially leading next-generation ASI as it is highly selective for aldosterone synthase and spares the cortisol pathway in humans.
Mene Pangalos, Executive Vice President BioPharmaceuticals R&D, AstraZeneca, said: “Excess levels of aldosterone are associated with hypertension and several cardiorenal diseases, including chronic kidney disease and coronary artery disease and being able to effectively reduce this would offer a much-needed treatment option for these patients.”
Marc de Garidel, CEO CinCor, said: “We are excited about the proposed acquisition of CinCor Pharma by AstraZeneca as we believe it offers the prospect of accelerating the development timeline and expanding the breadth of benefits patients with cardiorenal diseases might obtain from baxdrostat, if approved.”
